The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Open accessAbstract
RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT: In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–244 of 244
Solid-phase synthesis of siRNA oligonucleotides.
Beaucage, S. L. (2008) · PubMed · Cited by 55
Aberrant micro RNA expression in multiple myeloma
Dimopoulos, K., Gimsing, P., & Grønbæk, K. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12124 · Cited by 53
Tu, M., Ho, P. Y., Zhang, Q.-Y., Jian, C., Qiu, J.-X., Kim, E. J.-H., Bold, R. J., Gonzalez, F. J., Bi, H., & Yu, A. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.038 · Cited by 52
Self-citationMicroRNA-targeted therapeutics for lung cancer treatment
Xue, J., Yang, J., Luo, M., Cho, W. C. S., & Liu, X. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1263298 · Cited by 50
Functional Role of microRNAs in Regulating Cardiomyocyte Death
Kansakar, U., Varzideh, F., Mone, P., Jankauskas, S. S., & Santulli, G. (2022) · Cells · doi:10.3390/cells11060983 · Cited by 50
Xu, J., Sun, J., Ho, P. Y., Luo, Z., Ma, W., Zhao, W., Rathod, S., Fernandez, C. A., Venkataramanan, R., Xie, W., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.025 · Cited by 49
Self-citationSun, S., Wang, Y., Zhou, R., Deng, Z., Han, Y., Han, X., Tao, W., Yang, Z., Shi, C., Hong, D., et al. (2017) · Theranostics · doi:10.7150/thno.16357 · Cited by 47
Zhang, Q.-Y., Ho, P. Y., Tu, M., Jilek, J. L., Chen, Q., Zeng, S., & Yu, A.-M. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.026 · Cited by 46
Self-citationExosomes: Natural Carriers for siRNA Delivery
Kumar, L., Verma, S., Vaidya, B., & Gupta, V. (2015) · Current Pharmaceutical Design · doi:10.2174/138161282131151013190112 · Cited by 44
Beyond MicroRNAs: Emerging Role of Other Non-Coding RNAs in HPV-Driven Cancers
Casarotto, M., Fanetti, G., Guerrieri, R., Palazzari, E., Lupato, V., Steffan, A., Polesel, J., Boscolo‐Rizzo, P., & Fratta, E. (2020) · Cancers · doi:10.3390/cancers12051246 · Cited by 42
Enhancing adoptive T cell immunotherapy with microRNA therapeutics
Ji, Y., Hocker, J. D., & Gattinoni, L. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.006 · Cited by 41
Jilek, J. L., Zhang, Q.-Y., Tu, M., Ho, P. Y., Duan, Z., Qiu, J., & Yu, A. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.007 · Cited by 40
Self-citationNovel approaches for efficient in vivo fermentation production of noncoding RNAs
Yu, A., Batra, N., Tu, M., & Sweeney, C. A. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10350-3 · Cited by 39
Self-citationLovat, F., Nigita, G., Distefano, R., Nakamura, T., Gasparini, P., Tomasello, L., Fadda, P., Ibrahimova, N., Catricalà, S., Palamarchuk, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003597117 · Cited by 38
Li, M.-M., Wang, W.-P., Wu, W.-J., Huang, M., & Yu, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060145 · Cited by 37
Self-citationTu, M., Duan, Z., Liu, Z., Zhang, C., Bold, R. J., Gonzalez, F. J., Kim, E. J.-H., & Yu, A. (2020) · Molecular Pharmacology · doi:10.1124/molpharm.120.000130 · Cited by 37
Self-citationReijman, M. D., Schweizer, A., Peterson, A. L. H., Bruckert, E., Stratz, C., Defesche, J. C., Hegele, R. A., & Wiegman, A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac025 · Cited by 37 · cited 1×
“As a newly approved therapeutic, inclisiran is currently under several phase III studies to assess the efficacy, safety, and tolerability of long-term dosing including ORION-8 (NCT03814187), ORION-13 (NCT04659863) and ORION-16 (NCT04652726) (Brandts and Ray, 2021; Reijman et al., 2022).”
Function Control of Anti-microRNA Oligonucleotides Using Interstrand Cross-Linked Duplexes
Mie, Y., Hirano, Y., Kowata, K., Nakamura, A., Yasunaga, M., Nakajima, Y., & Komatsu, Y. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.11.003 · Cited by 35
Li, P.-C., Tu, M., Ho, P. Y., Batra, N., Tran, M., Qiu, J.-X., Wun, T., Lara, P. N., Hu, X., Yu, A.-X., et al. (2021) · Theranostics · doi:10.7150/thno.56596 · Cited by 35
Self-citationHashiro, S., Mitsuhashi, M., Chikami, Y., Kawaguchi, H., Niimi, T., & Yasueda, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10113-9 · Cited by 31
Clinical Implications and Outcomes of the Orion Phase Iii Trials
Brandts, J., & Ray, K. K. (2020) · Future Cardiology · doi:10.2217/fca-2020-0150 · Cited by 31
Jian, C., Tu, M., Ho, P. Y., Duan, Z., Zhang, Q., Qiu, J.-X., White, R. D., Wun, T., Lara, P. N., Lam, K. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16372 · Cited by 30
Self-citationRNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria
Sardh, E., & Harper, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13443 · Cited by 30
Recent early clinical drug development for acute kidney injury
Gallagher, K., O’Neill, S., Harrison, E. M., Ross, J. A., Wigmore, S. J., & Hughes, J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1274730 · Cited by 28
The role of microRNAs in photodynamic therapy of cancer
El‐Daly, S. M., Abba, M. L., & Gamal‐Eldeen, A. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.011 · Cited by 28
Bio responsive self-assembly of Au-miRNAs for targeted cancer theranostics
Cai, W., Feng, H., Yin, L., Wang, M., Jiang, X., Qin, Z., Liu, W., Li, C., Jiang, H., Weizmann, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102740 · Cited by 28
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., & Luijendijk, H. J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1787832 · Cited by 28
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk
Santulli, G., Jankauskas, S. S., & Gambardella, J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab014 · Cited by 27
Maguregui, A., & Abe, H. (2020) · ChemBioChem · doi:10.1002/cbic.202000009 · Cited by 26
Deng, L., Petrek, H. E., Tu, M., Batra, N., Yu, A., & Yu, A. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.027 · Cited by 25
Self-citationAdvances in time course extracellular production of human pre-miR-29b from Rhodovulum sulfidophilum
Pereira, P., Pedro, A. Q., Tomás, J., Maia, C. J., Queiroz, J. A., Figueiras, A., & de Sousa, F. P. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7350-x · Cited by 25
Investigational Therapies for Primary Hyperoxaluria
Kletzmayr, A., Ivarsson, M. E., & Leroux, J. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00268 · Cited by 24
Orellana, E. A., Li, C., Lisevick, A. B., & Kasinski, A. L. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1634956 · Cited by 21
Berk, C., Civenni, G., Wang, Y., Steuer, C., Catapano, C. V., & Hall, J. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0852 · Cited by 19
Petrek, H. E., Ho, P. Y., Batra, N., Tu, M., Zhang, Q., Qiu, J.-X., & Yu, A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114392 · Cited by 19
Self-citationCo-Expression and Co-Purification of Archaeal and Eukaryal Box C/D RNPs
Peng, Y., Yu, G., Tian, S., & Li, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103096 · Cited by 18
SiRNA Delivery Methods: Methods and Protocols
Shum, K., & Rossi, J. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3112-5 · Cited by 18
Alegre, F., Ormonde, A. R., Snider, K. M., Woolard, K., Yu, A., & Wittenburg, L. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209941 · Cited by 18
Self-citationGao, Y., He, X., Cai, B., Wang, L., Lv, Q., Hou, Y., Liu, F., Dai, T., & Kong, L. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.02.080 · Cited by 17
Wang, Z., Chen, X., Liu, J., Wang, Y., & Zhang, S. (2022) · Autoimmunity · doi:10.1080/08916934.2022.2051142 · Cited by 16
Hashiro, S., Mitsuhashi, M., & Yasueda, H. (2019) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2019.03.003 · Cited by 16
Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma
Weaver, D. T., Pishas, K. I., Williamson, D. F. K., Scarborough, J. A., Lessnick, S. L., Dhawan, A., & Scott, J. G. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008755 · Cited by 16
Single-pot enzymatic synthesis of Dicer-substrate siRNAs
Guiley, K. Z., Pratt, A. J., & MacRae, I. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1174 · Cited by 9
Marchi, R., Duarte, L., P, S., D, R. P. M., Ke, A., Hl, B., E, S., Hemadharsni.P, H. P., M, B., & Al, E. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.10.028 · Cited by 5
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Wang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21
Self-citation
Metadata
- Authors
- Traber, G. M., & Yu, A.-M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 384
- Issue
- 1
- Pages
- 133-154
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W4282944269
- Cited by
- 291
- References
- 244
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.